Hyperion Therapeutics

Horizon Pharma to buy Hyperion Therapeutics for $1.1 billion

DUBLIN, Ireland, and BRISBANE, Calif. — Horizon Pharma plc plans to acquire biopharmaceutical company Hyperion Therapeutics Inc. in a $1.1 billion cash deal. Horizon said Monday that the agreement will increase its number of products from five to seven, notably through the addition of Ravicti and Buphenyl to its orphan business unit. Ravicti and Buphenyl

Adheris Health